Totus Medicines Unlocks "Undruggable" Autoimmune Disease Target with AI

BOSTON, MA – April 16, 2026 – In a development that could reshape the treatment landscape for millions suffering from autoimmune diseases, clinical-stage biotech firm Totus Medicines today unveiled promising preclinical data for a novel, first-in-class oral therapy. The data, presented at the American Association of Immunologists (AAI) IMMUNOLOGY2026 annual meeting, details a small molecule inhibitor designed to shut down Interferon Regulatory Factor 5 (IRF5), a protein long considered a high-value but “undruggable” target at the heart of conditions like lupus and rheumatoid arthritis.

The announcement highlights not only a potential therapeutic breakthrough but also the formidable power of the company’s artificial intelligence-driven drug discovery engine, which advanced the compound from initial concept to in vivo proof-of-concept in an astonishing nine months.

Cracking a Long-Standing Immunological Code

For decades, IRF5 has been a tantalizing target for immunologists and drug developers. As a key transcription factor, it acts as a master switch in the immune system, orchestrating the production of Type I interferons and other pro-inflammatory cytokines that drive chronic inflammation. Genetic studies have repeatedly linked variations in the IRF5 gene to an increased risk of developing systemic lupus erythematosus (SLE), Sjögren’s disease, rheumatoid arthritis (RA), and inflammatory bowel disease.

Despite its central role in pathology, IRF5 has defied the efforts of traditional drug discovery. The protein lacks a conventional, well-defined pocket for small molecules to bind to, and its complex activation mechanism has made it notoriously difficult to inhibit selectively. This has left a significant unmet need for patients, who often rely on broad immunosuppressants with significant side effects or biologic drugs that target single downstream cytokines, an approach that doesn't work for everyone.

A specific, oral therapy that could neutralize IRF5 at the source has been a holy grail in the field, promising a more precise and potentially more effective way to manage these debilitating diseases. Totus Medicines believes it has finally cracked this code.

AI-Powered Discovery at Unprecedented Speed

The key to this rapid progress lies in Totus's proprietary OmniDEL™ platform, a sophisticated system that marries DNA-encoded libraries with advanced artificial intelligence. The platform screens billions of unique covalent compounds—molecules designed to form a permanent, secure bond with their target—directly within cells to identify promising drug candidates. AI and machine learning algorithms then analyze the vast datasets to predict efficacy, selectivity, and other critical drug-like properties, dramatically accelerating the design-build-test cycle.

The company’s ability to move from target identification to animal model validation in under a year showcases a significant leap in efficiency compared to traditional drug discovery timelines, which often span several years. This speed is critical in a competitive field and underscores the transformative potential of AI in tackling medicine's most complex challenges.

“IRF5 represents a highly compelling but previously undruggable target at the center of autoimmune pathology. Here we demonstrate that our first-in-class covalent small molecule can selectively and effectively inhibit IRF5, opening a new therapeutic avenue for patients with autoimmune and inflammatory diseases,” said Dr. Zelanna Goldberg, Chief Medical Officer of Totus Medicines, in a press release. “Selective covalent targeting of IRF5 has the potential to address multiple clinically validated drivers of autoimmune disease – including TNFα, IL-6, IL-12, and Type I interferons – with a single oral therapy.”

A Crowded Field for a High-Value Target

While the data from Totus is a significant milestone, the company is not alone in the race to drug IRF5. The protein's importance has attracted other well-funded biotechs, each employing a unique technological approach. HotSpot Therapeutics, in a major collaboration with AbbVie, is developing a small molecule that targets a novel allosteric site on the protein, a hidden pocket discovered through its own proprietary platform. Meanwhile, Kymera Therapeutics is advancing KT-579, a first-in-class oral degrader that uses the body's own machinery to destroy the IRF5 protein entirely, with plans to enter the clinic in early 2026.

Totus’s approach—a covalent inhibitor—offers a distinct mechanism. By forming a permanent bond, it can achieve potent and durable target inhibition, potentially leading to less frequent dosing and a cleaner side-effect profile. The company's claim to a first-in-class covalent, oral IRF5 inhibitor carves out its specific niche in this competitive but promising therapeutic area. The simultaneous development of these different strategies by multiple companies highlights the intense scientific and commercial interest in finally conquering IRF5.

From Preclinical Promise to Patient Hope

The poster presented at the AAI conference, titled “Targeting IRF5 with a selective covalent oral small molecule attenuates Type I interferon and pro-inflammatory cytokine responses in human PBMCs and mice,” provided the first public look at the scientific evidence. Key highlights included confirmation of covalent binding via mass spectrometry and high selectivity for IRF5 over related proteins, which is crucial for avoiding off-target side effects. The molecule successfully blocked the secretion of inflammatory cytokines in human immune cells and, importantly, demonstrated this effect in living mouse models, including those with humanized immune systems.

This IRF5 program is not Totus's first foray into drugging difficult targets. The company is already in Phase 1 clinical trials with its lead asset, TOS-358, the first-ever covalent inhibitor of PI3Kα, a key driver in several cancers. The progress of that program, combined with a strong financial foundation—including a total of $108 million raised in Series A and B funding—and a strategic research collaboration with pharmaceutical giant Eli Lilly, provides the company with the experience and resources to advance its new autoimmune candidate toward the clinic.

For the millions of patients navigating the daily challenges of autoimmune disease, the convergence of AI, novel chemistry, and a deeper understanding of immunology represents a new horizon of hope. While the journey from a preclinical poster to an approved medicine is long and fraught with challenges, the data presented today marks a crucial step forward in the quest to deliver a safe, effective, and convenient oral therapy for some of medicine’s most persistent and painful conditions.